Literature DB >> 17382525

Involvement of transient receptor potential proteins in cardiac hypertrophy.

Romain Guinamard1, Patrick Bois.   

Abstract

Cardiac hypertrophy is an adaptive process that occurs in response to increased physical stress on the heart. Hypertrophy, which may be induced by hypertension among other factors, is characterized by an increase in left ventricular mass and an associated increase in force production capacity. However, as sustained cardiac hypertrophy may lead to heart failure and sudden death, an understanding of the molecular processes involved in both the onset and consequences of hypertrophy is of significant importance. Calcium is a key player in the process underlying the development of cardiac hypertrophy. Recently, several Transient Receptor Potential proteins (TRPs), including calcium-permeable and calcium-regulated ion channels, have been shown to be related to various aspects of cardiac hypertrophy. TRPs are implicated in the development of cardiac hypertrophy (TRPC1, TRPC3, TRPC6), the electrophysiological perturbations associated with hypertrophy (TRPM4) and the progression to heart failure (TRPC7). This review describes the major characteristics of cardiac hypertrophy and focuses on the roles of TRPs in the physiological processes underlying hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17382525     DOI: 10.1016/j.bbadis.2007.02.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  23 in total

1.  The transient receptor potential (TRP) channel TRPC3 TRP domain and AMP-activated protein kinase binding site are required for TRPC3 activation by erythropoietin.

Authors:  Iwona Hirschler-Laszkiewicz; Qin Tong; Kathleen Waybill; Kathleen Conrad; Kerry Keefer; Wenyi Zhang; Shu-jen Chen; Joseph Y Cheung; Barbara A Miller
Journal:  J Biol Chem       Date:  2011-07-14       Impact factor: 5.157

2.  TRPC6 mutations associated with focal segmental glomerulosclerosis cause constitutive activation of NFAT-dependent transcription.

Authors:  Johannes Schlöndorff; Donato Del Camino; Robert Carrasquillo; Vanessa Lacey; Martin R Pollak
Journal:  Am J Physiol Cell Physiol       Date:  2009-01-07       Impact factor: 4.249

3.  Could early ischemic arrhythmia triggered by purinergic activation of the transient receptor potential channels be prevented by creatine?

Authors:  Guy Vassort; Patrice Bideaux; Julio Alvarez
Journal:  Exp Clin Cardiol       Date:  2010

Review 4.  Cytoskeletal regulation of TRPC channels in the cardiorenal system.

Authors:  Jonathan A Stiber; Youlan Tang; TianYu Li; Paul B Rosenberg
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

5.  Induction of a novel cation current in cardiac ventricular myocytes by flufenamic acid and related drugs.

Authors:  R Macianskiene; A Gwanyanya; K R Sipido; J Vereecke; K Mubagwa
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

Review 6.  Cardioprotective actions of cyclic GMP: lessons from genetic animal models.

Authors:  Christian F Deschepper
Journal:  Hypertension       Date:  2009-12-14       Impact factor: 10.190

7.  9-phenanthrol inhibits human TRPM4 but not TRPM5 cationic channels.

Authors:  T Grand; M Demion; C Norez; Y Mettey; P Launay; F Becq; P Bois; R Guinamard
Journal:  Br J Pharmacol       Date:  2008-02-25       Impact factor: 8.739

Review 8.  Roles of TRP channels in the development of cardiac hypertrophy.

Authors:  Motohiro Nishida; Hitoshi Kurose
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-04       Impact factor: 3.000

9.  Differential expression of TRPC channels in the left ventricle of spontaneously hypertensive rats.

Authors:  Fang-fang Liu; Zhi-yong Ma; Duo-ling Li; Jin-bo Feng; Kai Zhang; Rong Wang; Wei Zhang; Li Li; Yun Zhang
Journal:  Mol Biol Rep       Date:  2009-09-13       Impact factor: 2.316

10.  Ca(2+) influx through L-type Ca(2+) channels and transient receptor potential channels activates pathological hypertrophy signaling.

Authors:  Hui Gao; Fang Wang; Wei Wang; Catherine A Makarewich; Hongyu Zhang; Hajime Kubo; Remus M Berretta; Larry A Barr; Jeffery D Molkentin; Steven R Houser
Journal:  J Mol Cell Cardiol       Date:  2012-08-21       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.